Download presentation
Presentation is loading. Please wait.
Published byGöran Nilsson Modified over 5 years ago
1
Inhalation of low-dose endotoxin favors local TH2 response and primes airway phagocytes in vivo
Neil E. Alexis, PhD, John C. Lay, PhD, Martha Almond, RRT, David B. Peden, MD, MS Journal of Allergy and Clinical Immunology Volume 114, Issue 6, Pages (December 2004) DOI: /j.jaci Copyright © 2004 American Academy of Allergy, Asthma and Immunology Terms and Conditions
2
Fig 1 Individual subject (n=9) phagocytosis values for monocytes (A) and macrophages (B) at increasing doses of CCRE (0, 2500, 5000, and 10,000 EU). Mean values are shown as a horizontal dash (–) at each dose of CCRE. Phagocytosis is the ability to phagocytize IgG-opsonized zymosan (S cerevisiae) particles (expressed on the y axis as MFI). Journal of Allergy and Clinical Immunology , DOI: ( /j.jaci ) Copyright © 2004 American Academy of Allergy, Asthma and Immunology Terms and Conditions
3
Fig 2 Individual subject (n=9) CD11b values expressed as MFI for monocytes (A) and neutrophils (B) at increasing doses of CCRE (0, 2500, 5000, and 10,000 EU). Mean values are shown as a horizontal dash (–) at each dose of CCRE. Journal of Allergy and Clinical Immunology , DOI: ( /j.jaci ) Copyright © 2004 American Academy of Allergy, Asthma and Immunology Terms and Conditions
4
Fig 3 Individual subject (n=9) mCD14 values expressed as MFI for monocytes (A) and macrophages (B) at increasing doses of CCRE (0, 2500, 5000, and 10,000 EU). Mean values are shown as a horizontal dash (–) at each does of CCRE. Journal of Allergy and Clinical Immunology , DOI: ( /j.jaci ) Copyright © 2004 American Academy of Allergy, Asthma and Immunology Terms and Conditions
5
Fig 4 Effect of inhalation of 10,000 EU of CCRE on the mean ± SEM levels (picograms per milligram wet weight sputum) of IFN-γ (A) and IL-13 (B) in 9 subjects. Journal of Allergy and Clinical Immunology , DOI: ( /j.jaci ) Copyright © 2004 American Academy of Allergy, Asthma and Immunology Terms and Conditions
Similar presentations
© 2024 SlidePlayer.com. Inc.
All rights reserved.